Skip to main content

30-day Risk Standardized Morbidity and Mortality Composite following Transcatheter Aortic Valve Replacement (TAVR)

CBE ID
3610
1.4 Project
Cardiovascular
Endorsed
Endorsement Status
Endorsed
1.1 New or Maintenance
Maintenance
E&M Cycle
Spring 2021
Is Under Review
No
Next Planned Maintenance Review
Cardiovascular Spring 2025
1.3 Measure Description

The TAVR 30-day morbidity/mortality composite is a hierarchical, multiple outcome risk model that estimates risk standardized results (reported as a “site difference”) for the purpose of benchmarking site performance. This measure estimates hospital risk standardized site difference for 5 endpoints (death from all causes, stroke, major or life-threatening bleeding, acute kidney injury, moderate or severe paravalvular aortic regurgitation) within 30 days following transcatheter aortic valve replacement. The measure uses clinical data available in the STS/ACC TVT Registry for risk adjustment for the purposes of benchmarking site to site performance on a rolling 3-year timeframe.

    • 1.14 Numerator

      A composite outcome including all-cause death, stroke, major or life threatening bleeding, acute kidney injury, moderate or severe paravalvular aortic regurgitation within 30 days following transcatheter aortic valve replacement (TAVR).

      If a patient experiences multiple outcomes captured in the overall rank composite measure, the outcome with the highest rank is assigned.

    • 1.15 Denominator

      Patients who had TAVR.

    • Exclusions

      Hospitals are excluded if they do not meet eligibility criteria noted in S.7.
      Patients are excluded if any of the following occur:
      1) They did not have a first-time TAVR in the episode of care (admission),
      2) The TAVR was subsequent to another procedure in the Registry (other TAVR, Mitral Leaflet Clip and/or TMVR) during that admission.
      3) The patient is readmitted for a repeat TAVR (re-admission) and the initial TAVR was performed during the rolling 3-year timeframe for the measure.
      4) They are in TVT Registry sponsored research studies (identified with research study=yes and research study device used during procedure).

    • Most Recent Endorsement Activity
      Endorsed Cardiovascular Spring 2021
      Initial Endorsement
      Last Updated